Cargando…
HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic Opportunities
Human immunodeficiency virus type 1 (HIV) infection presently affects more that 40 million people worldwide, and is associated with central nervous system (CNS) disruption in at least 30% of infected individuals. The use of highly active antiretroviral therapy has lessened the incidence, but not the...
Autores principales: | Lindl, Kathryn A., Marks, David R., Kolson, Dennis L., Jordan-Sciutto, Kelly L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914283/ https://www.ncbi.nlm.nih.gov/pubmed/20396973 http://dx.doi.org/10.1007/s11481-010-9205-z |
Ejemplares similares
-
Activation status of integrated stress response pathways in neurones and astrocytes of HIV‐associated neurocognitive disorders (HAND) cortex
por: Akay, C., et al.
Publicado: (2012) -
Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND)
por: Kolson, Dennis L.
Publicado: (2022) -
Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIV-Associated Neurocognitive Disorders
por: Ambegaokar, Surendra S, et al.
Publicado: (2014) -
Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders
por: McGuire, Jennifer L, et al.
Publicado: (2015) -
Targeting the Glutamatergic System for the Treatment of HIV-Associated Neurocognitive Disorders
por: Potter, Michelle C., et al.
Publicado: (2013)